Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. is holding a virtual annual stockholder meeting on May 12, 2026 at 8:30 AM Eastern Time. Stockholders will vote on electing three Class II directors for three-year terms and ratifying Grant Thornton as independent registered public accounting firm for fiscal 2026.
The board has seven members, six of whom are independent, and is divided into three staggered classes. The proxy describes virtual-only access procedures, voting mechanics for record and beneficial holders, and quorum and vote standards. It also outlines 2025 executive pay, which combines base salary, cash incentives tied to revenue, EBITDA and debt prepayment, and equity awards in the form of restricted stock units and performance-based units tied to relative total shareholder return or stock price performance.
Airsculpt Technologies, Inc. major holder Jorey Chernett reported an open-market purchase of 20,000 shares of Common Stock at a weighted average price of $2.60 per share. After this transaction, he directly holds 7,013,761 shares of Airsculpt common stock.
Jashnani Yogesh reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. reported that Chief Executive Officer Yogesh Jashnani received a grant of 238,095 shares of Common Stock in the form of Restricted Stock Units on April 8, 2026 under the company’s 2021 Equity Incentive Plan. These RSUs will vest in three equal annual installments starting on April 8, 2027, contingent on his continued employment. Following this equity award, Jashnani directly holds 696,475 shares of Airsculpt common stock.
Arthur Michael J reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. reported that Chief Financial Officer Arthur Michael J received a grant of 68,027 shares of Common Stock as Restricted Stock Units on April 8, 2026 under the 2021 Equity Incentive Plan. The RSUs will vest in three equal annual installments beginning April 8, 2027, subject to his continued employment. Following this award, he directly holds 215,086 shares of common stock.
WADMAN BRENT R reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. reported that its General Counsel, Brent R. Wadman, received an equity award on April 8, 2026. He was granted 55,272 Restricted Stock Units (RSUs) under the company’s 2021 Equity Incentive Plan, with no cash paid per share.
The RSUs will vest in three equal annual installments beginning on April 8, 2027, as long as he remains employed by the company. Following this grant, he reports ownership of 55,272 shares of common stock directly tied to this award.
Airsculpt Technologies, Inc. ten percent owner Jorey Chernett bought 60,000 shares of common stock in an open-market purchase. The weighted average price was $2.93 per share, with individual trades between $2.91 and $2.94. Following this transaction, Chernett directly holds 6,993,761 shares of Airsculpt common stock.
Airsculpt Technologies, Inc. major shareholder Jorey Chernett reported an open-market purchase of 90,000 shares of common stock at a weighted average price of $2.82 per share. Following this transaction, Chernett directly holds 6,933,761 shares of Airsculpt common stock.
The shares were bought in multiple trades at prices ranging from $2.67 to $3.00 per share, with the reported price representing the rounded weighted average across those individual transactions.
AirSculpt Technologies, Inc. filed an amended current report to correct errors in certain non-GAAP figures in its earlier earnings release, then reiterated updated fourth-quarter and full-year 2025 results and 2026 guidance. The corrections reduced Adjusted EBITDA, Adjusted EBITDA Margin and Adjusted Net (Loss)/Income for the three and twelve months ended December 31, 2025, mainly due to a one-time non-cash adjustment tied to closing its London facility and a tax-effect adjustment.
For Q4 2025, case volume fell 15.0% to 2,604 and revenue declined 14.6% to $33.4 million, but net loss improved to $1.3 million from $5.0 million a year earlier; Adjusted EBITDA was roughly breakeven at $(0.1) million. For full-year 2025, cases fell 15.6% to 11,852, revenue declined 15.8% to $151.8 million, net loss widened to $11.7 million, and Adjusted EBITDA decreased to $12.5 million.
The company ended 2025 with $8.4 million in cash, $56.0 million of gross debt and $87.7 million of stockholders’ equity, and remained in compliance with debt covenants. In Q1 2026, it raised $14.8 million via its at-the-market share program and paid down $11.0 million of debt, reducing gross debt to about $45.0 million. Management projects 2026 revenue of $151–$157 million and Adjusted EBITDA of $15–$17 million, and notes that the non-GAAP corrections do not affect GAAP financial statements or 2026 forward-looking guidance.
AirSculpt Technologies, Inc. filed an amended annual report to correct errors in the presentation of certain non‑GAAP financial measures for 2025. A one-time non‑cash adjustment tied to closing its London facility overstated Adjusted EBITDA and Adjusted Net (Loss)/Income by approximately $2.6 million and Adjusted EBITDA Margin by about 1.7%.
An additional tax-effect adjustment overstated Adjusted Net (Loss)/Income by $2.7 million, resulting in a net overstatement of about $0.1 million for 2025. The company states these errors did not affect its GAAP consolidated financial statements or the related audit opinion and did not change previously disclosed conclusions on internal control over financial reporting.